Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

May 20, 2020

Study Completion Date

January 10, 2021

Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
DRUG

Vitamin E

Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.

DRUG

Ursodeoxycholic acid

is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)

DRUG

Pentoxifylline

"it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription"

Trial Locations (1)

33511

Hepatology, gastroenterology and infectious diseases department at Kafrelsheikh University Hospital, Cairo

All Listed Sponsors
lead

Kafrelsheikh University

OTHER

NCT04977661 - Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients | Biotech Hunter | Biotech Hunter